Sedana Medical AB (publ) (SEDANA.ST)
SEK 16.0
(0.38%)
SEK 16.0
(0.38%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -65.54 Million SEK | 35.95% |
| 2022 | -103.93 Million SEK | -69.84% |
| 2021 | -61.19 Million SEK | -184.1% |
| 2020 | -21.54 Million SEK | -28.78% |
| 2019 | -16.72 Million SEK | -103.04% |
| 2018 | -8.23 Million SEK | -136.2% |
| 2017 | -3.48 Million SEK | -664.37% |
| 2016 | 618 Thousand SEK | 144.56% |
| 2015 | -1.38 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -20.6 Million SEK | -52.98% |
| 2024 Q2 | -16.87 Million SEK | 18.09% |
| 2024 Q3 | -14.3 Million SEK | 15.21% |
| 2023 Q2 | 2.9 Million SEK | 117.81% |
| 2023 Q1 | -16.29 Million SEK | 23.47% |
| 2023 Q4 | -13.46 Million SEK | 25.56% |
| 2023 Q3 | -18.09 Million SEK | -723.15% |
| 2023 FY | -66.56 Million SEK | 35.95% |
| 2022 Q1 | -22.06 Million SEK | -18.08% |
| 2022 Q2 | -29.81 Million SEK | -35.13% |
| 2022 FY | -103.93 Million SEK | -69.84% |
| 2022 Q3 | -30.76 Million SEK | -3.21% |
| 2022 Q4 | -21.29 Million SEK | 30.79% |
| 2021 Q2 | -16.37 Million SEK | -57.98% |
| 2021 FY | -61.19 Million SEK | -184.1% |
| 2021 Q1 | -10.36 Million SEK | -32.44% |
| 2021 Q4 | -18.68 Million SEK | -16.2% |
| 2021 Q3 | -16.07 Million SEK | 1.78% |
| 2020 Q4 | -7.82 Million SEK | 33.13% |
| 2020 FY | -21.54 Million SEK | -28.78% |
| 2020 Q3 | -11.7 Million SEK | -510.17% |
| 2020 Q2 | -1.91 Million SEK | -2431.1% |
| 2020 Q1 | 82.25 Thousand SEK | 101.63% |
| 2019 Q3 | -5.09 Million SEK | -50.84% |
| 2019 Q2 | -3.37 Million SEK | 7.75% |
| 2019 Q4 | -5.03 Million SEK | 1.09% |
| 2019 FY | -16.72 Million SEK | -103.04% |
| 2019 Q1 | -3.66 Million SEK | -49.37% |
| 2018 Q1 | -1.72 Million SEK | 9.54% |
| 2018 Q2 | -2 Million SEK | -16.03% |
| 2018 Q3 | -2.05 Million SEK | -2.17% |
| 2018 Q4 | -2.45 Million SEK | -19.48% |
| 2018 FY | -8.23 Million SEK | -136.2% |
| 2017 Q2 | 408.39 Thousand SEK | 51.26% |
| 2017 Q3 | -2.25 Million SEK | -651.83% |
| 2017 Q4 | -1.91 Million SEK | 15.14% |
| 2017 Q1 | 270 Thousand SEK | -67.58% |
| 2017 FY | -3.48 Million SEK | -664.37% |
| 2016 Q1 | 1.07 Million SEK | 0.0% |
| 2016 FY | 618 Thousand SEK | 144.56% |
| 2016 Q4 | 832.73 Thousand SEK | 262.83% |
| 2016 Q2 | -781.4 Thousand SEK | -172.49% |
| 2016 Q3 | -511.41 Thousand SEK | 34.55% |
| 2015 FY | -1.38 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.55 Million SEK | 15.481% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 121.805% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 121.805% |
| Arcoma AB | 4.66 Million SEK | 1506.588% |
| Bactiguard Holding AB (publ) | -131.93 Million SEK | 50.318% |
| BICO Group AB (publ) | -618.3 Million SEK | 89.399% |
| Boule Diagnostics AB (publ) | 39.27 Million SEK | 266.914% |
| CellaVision AB (publ) | 167.05 Million SEK | 139.238% |
| Clinical Laserthermia Systems AB (publ) | -65.93 Million SEK | 0.585% |
| Chordate Medical Holding AB (publ) | -29.57 Million SEK | -121.655% |
| C-Rad AB (publ) | 44.24 Million SEK | 248.149% |
| Duearity AB (publ) | -25.76 Million SEK | -154.423% |
| Dignitana AB (publ) | -15.02 Million SEK | -336.224% |
| Episurf Medical AB (publ) | -94.8 Million SEK | 30.858% |
| Getinge AB (publ) | 3.81 Billion SEK | 101.719% |
| Scandinavian Real Heart AB (Publ) | -68.44 Million SEK | 4.235% |
| Iconovo AB (publ) | -45.77 Million SEK | -43.188% |
| Integrum AB (publ) | 6.51 Million SEK | 1106.505% |
| Luxbright AB (publ) | -25.8 Million SEK | -154.014% |
| Mentice AB (publ) | -679 Thousand SEK | -9553.461% |
| OssDsign AB (publ) | -91.95 Million SEK | 28.719% |
| Paxman AB (publ) | 12.61 Million SEK | 619.431% |
| Promimic AB (publ) | -9.11 Million SEK | -618.875% |
| Qlife Holding AB (publ) | -168.69 Million SEK | 61.145% |
| SciBase Holding AB (publ) | -53.93 Million SEK | -21.521% |
| ScandiDos AB (publ) | -13.48 Million SEK | -386.146% |
| Sectra AB (publ) | 518.49 Million SEK | 112.642% |
| Senzime AB (publ) | -133.74 Million SEK | 50.991% |
| SpectraCure AB (publ) | -21.35 Million SEK | -206.997% |
| Stille AB | 44.95 Million SEK | 245.816% |
| Vitrolife AB (publ) | -3.58 Billion SEK | 98.174% |
| Xvivo Perfusion AB (publ) | 38.5 Million SEK | 270.225% |